本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Akari Therapeutics PLC

5.12
+0.510011.06%
盤後4.83-0.2853-5.57%19:59 EDT
成交量:1.31萬
成交額:6.47萬
市值:586.00萬
市盈率:-0.25
高:5.27
開:4.61
低:4.61
收:4.61
52周最高:63.20
52周最低:3.25
股本:114.45萬
流通股本:86.33萬
量比:1.09
換手率:1.52%
股息:- -
股息率:- -
每股收益(TTM):-20.5537
每股收益(LYR):-20.5537
淨資產收益率:-68.43%
總資產收益率:-15.36%
市淨率:0.21
市盈率(LYR):-0.25

資料載入中...

2024/05/01

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/05/01

重要事件披露

Form 8-K - Current report
2024/04/11

重要事件披露

Form 8-K - Current report
2024/04/01

重要事件披露

Form 8-K - Current report
2024/03/29

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/11

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/11

重要事件披露

Form 8-K - Current report
2024/03/05

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

重要事件披露

Form 8-K - Current report
2024/01/05

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/01/03

重要事件披露

Form 8-K - Current report
2023/10/25

SEC問詢函

Form CORRESP - Correspondence
2023/10/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/10/13

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/31

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/01

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/14

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/11/07

SEC問詢函

CORRESP [Cover] - Correspondence